Dynavax Technologies Corp. (NASDAQ:DVAX)’s share price was up 3.6% during mid-day trading on Thursday . The company traded as high as $16.21 and last traded at $16.20, with a volume of 240,590 shares traded. The stock had previously closed at $15.63.

A number of equities analysts have issued reports on DVAX shares. Zacks Investment Research cut Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a report on Tuesday. JPMorgan Chase & Co. cut Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $29.00 to $22.00 in a report on Wednesday, April 27th. Royal Bank Of Canada cut Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $48.00 to $17.00 in a report on Wednesday, April 27th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $60.00 target price on shares of Dynavax Technologies Corp. in a report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $32.20.

The company’s 50 day moving average price is $15.42 and its 200-day moving average price is $17.05. The company’s market cap is $625.19 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.07. The firm earned $2.65 million during the quarter, compared to analysts’ expectations of $1.58 million. During the same period in the prior year, the firm earned ($0.80) earnings per share. Dynavax Technologies Corp.’s revenue for the quarter was up 70.8% on a year-over-year basis. Equities research analysts expect that Dynavax Technologies Corp. will post ($2.96) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Dynavax Technologies Corp. stock. Trexquant Investment LP increased its position in Dynavax Technologies Corp. (NASDAQ:DVAX) by 14.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,200 shares of the biopharmaceutical company’s stock after buying an additional 8,911 shares during the period. Trexquant Investment LP owned 0.18% of Dynavax Technologies Corp. worth $1,696,000 at the end of the most recent reporting period.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.